CEBPA and acute myeloid leukemia: BM AML cells at diagnosis consisted of heterogeneous subclones harboring mutations in CEBPA (E309dupGAG 43.7% and S28Afs 48.8%), GATA2R330L (VAF, 47.7%), and WT1L378Dfs (VAF, 8.9%).